Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B.
Matteo S CarlinoAlexander M MenziesVictoria AtkinsonJonathan S CebonMichael B JamesonBernard M FitzharrisCatriona M McNeilAndrew G HillAntoni RibasMichael B AtkinsJohn A ThompsonWen-Jen HwuF Stephen HodiAlexander D GuminskiRichard KeffordHaiyan WuNageatte IbrahimBlanca Homet MorenoGeorgina V LongPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Standard-dose pembrolizumab plus reduced-dose ipilimumab demonstrated robust antitumor activity, durable response, and favorable long-term survival with manageable toxicity.